In a recent conversation with Jeff Elton, CEO of ConcertAI, he discussed changes to the pharmeceutical industry resulting from the COVID-19 pandemic. Both RWE (real world evidence) and RWD (real world data) provide remarkable insight regarding patient care and outcomes. RWE provides a possible solution for postponed or altered clinical trials, perhaps even more so than RWD. Elton emphasizes the need for designing studies that have a low burden for patients.
According to Jeff Elton, “Researchers have been using RWE to help inform study design, and to develop solutions to conduct studies in a different way,” Elton said. “As horrific as the pandemic has been in many ways, it also has helped to force more innovations out of the system.” Read more here.
(Source: Jenni Spinner, Outsourcing-Pharma, 2/16/21)